Biopharma Firms Reported Quarterly Financial Results

Companies revealed third quarter 2026 earnings while analysts evaluated ongoing M&A activity and recent drug approvals.

Updated on Oct. 13, 2026 in Biotech

Biopharma Firms Reported Quarterly Financial Results

Live Poll

Is now a good time to increase investments in biotech stocks given their current record valuations?

Biopharmaceutical companies across the United States have begun reporting third quarter 2026 earnings as the industry shifts toward validated biotech targets. The sector saw significant activity following a 2025 landscape that included $136 billion in M&A deals across 57 transactions.

Why it matters

Rising valuations are driving increased business development, with firms focusing on assets with near-term data readouts. Additionally, market demand for regulatory fast passes has elevated the value of priority review vouchers, as seen in the recent $210 million sale by Ultragenyx.

Jazz Pharmaceuticals faces an anticipated $800 million in-process R&D charge while expecting $1.22 billion in Q3 earnings. Meanwhile, Revolution Medicines is projected to report $14 million in initial sales for Rasonque, trailing the $20 million consensus estimate.

The players

Jazz Pharmaceuticals

This biopharmaceutical company focuses on developing life-changing medicines for people with serious diseases.

Ultragenyx

This biopharmaceutical company is dedicated to the development of novel therapies for patients with rare and ultra-rare genetic diseases.

Revolution Medicines

This company specializes in the development of targeted therapies for patients with cancer driven by RAS-addicted tumors.

Merck

This multinational pharmaceutical company is a global leader in the development and manufacturing of medicines and vaccines.

Johnson and Johnson

This multinational corporation develops medical devices, pharmaceuticals, and consumer packaged goods.

The details

The sector has been bolstered by FDA approvals, including Rasonque for pancreatic cancer, Ziihera for gastroesophageal adenocarcinoma, and gene therapies Fayuvi and Genglycos. Ultragenyx is currently executing an expense reduction plan to drive toward profitability by 2027.

August 2026: Jazz Pharmaceuticals acquired Actio Biosciences.
October 13, 2026: Johnson and Johnson held an earnings conference call.
October 23-27, 2026: Merck presented oncology data at the ESMO Congress.
October 26, 2026: Merck hosted an investor call during the ESMO Congress.
October 29, 2026: Merck reports quarterly earnings.

The Tech Race

The current quarterly results reflect an industry shift toward prioritized dealmaking, following the 2025 record of $136 billion in M&A activity across 57 transactions. Firms are increasingly competing to acquire validated assets with near-term data readouts to stay ahead in the sector.

The approval of new drugs like Ziihera, which targets a patient population of approximately 8,000 in the U.S., provides new treatment options for patients with gastroesophageal adenocarcinoma. These developments highlight how industry dealmaking directly influences the availability of specialized medical therapies.

The takeaway

The biopharma industry is currently prioritizing near-term clinical success and fiscal discipline as companies work toward long-term profitability. Investors and patients should track how these high-stakes acquisitions and asset reallocations impact the availability of new, specialized drug therapies.